45. Benson S.C., Iguchi R., Ho C.I. et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens. 2008 May;26(5):973-80. doi: 10.1097/HJH.0b013e3282f56ba5. www.ncbi.nlm.nih.gov/ pubmed/18398340 (дата обращения: 04.02.2021).
46. Wang J.G., Staessen J.A., Li Y. et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006 Jul;37(7):1933-40. doi: 10.1161/01.STR.0000227223.90239.13. www.ncbi.nlm. nih.gov/pubmed/16763185 (дата обращения: 04.02.2021).
47. Frampton J.E. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-000000000-00000. www. ncbi.nlm.nih.gov/pubmed/21504246 (дата обращения: 04.02.2021).
48. Volpe M. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? QJM. 2012 Jan;105(1):11–27. doi: 10.1093/qjmed/hcr190. www.ncbi. nlm.nih.gov/pubmed/22011630 (дата обращения: 04.02.2021).
49. Spindler S.R., Mote P.L., Flegal J.M. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. Age (Dordr). 2016 Dec;38(5–6):379–391. doi: 10.1007/s11357-016-9948-4. www.ncbi.nlm. nih.gov/pubmed/27590905 (дата обращения: 04.02.2021).
50. Janie M., Lunder M., Sabovic M. A low-dose combination of fluvastatin and valsartan: a new “drug”. and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. www.ncbi.nlm.nih.gov/ pubmed/25821790 (дата обращения: 04.02.2021).
51. Lunder M., Janie M., Jug B., Sabovic M. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med. 2012 Apr;23(3):261-6. doi: 10.1016/j.ejim.2011.11.011. www.ncbi.nlm.nih.gov/ pubmed/22385885 (дата обращения: 04.02.2021).
52. Janie M., Lunder M., Sabovic M. A new anti-ageing strategy focused on prevention of arterial ageing in the middle-aged population. Med Hypotheses. 2013 Jun;80(6):837-40. doi: 10.1016/j.mehy.2013.03.028. www.ncbi.nlm.nih.gov/pubmed/23587479 (дата обращения: 04.02.2021).
53. Lunder M., Janie M., Habjan S., Sabovic M. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males-a pilot study. Atherosclerosis. 2011 Apr;215(2):446-51. doi: 10.1016/j.atherosclerosis.2010.12.041. www.ncbi.nlm.nih.gov/pubmed/21300350 (дата обращения: 04.02.2021).
54. Savie V., Erzen B., Janie M. et al. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients. Diab Vasc Dis Res. 2013 Sep;10(5):420-5. doi: 10.1177/1479164113485102. www. ncbi.nlm.nih.gov/pubmed/23811602 (дата обращения: 04.02.2021).
55. Pasternak R.C., Smith S.C. Jr., Bairey-Merz C.N. et al. ACC/aHa/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002 Aug 7;40(3):567-72. doi: 10.1016/s0735-1097(02)02030-2. www.ncbi.nlm.nih.gov/pubmed/12142128 (дата обращения: 04.02.2021).
56. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001 Feb 13;103(6):904-12. doi: 10.1161/01.cir.103.6.904. www.ncbi.nlm.nih.gov/ pubmed/11171802 (дата обращения: 04.02.2021).
57. Zhou J., Cheng M., Liao YH. et al. Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. PLoS One. 2013 May 21;8(5):e63126. doi: 10.1371/journal.pone.0063126. Print 2013. www.ncbi.nlm.nih. gov/pubmed/23704894 (дата обращения: 04.02.2021).
58. 1. WO2012116985 – treatment of arterial ageing by combination of raas inhibitor and HMG-CoA reductase inhibitor. (Электронный ресурс) URL: https://patentscope. wipo.int/search/en/detail.jsf?docId=WO2012116985&_cid=P21-K5BAB1-64252-1 (дата обращения: 04.02.2021).
59. Liu Z., Zhao Y., Wei F. et al. Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis. 2014 Mar;233(1):291-9. doi: 10.1016/j.atherosclerosis.2013.12.004. www.ncbi.nlm.nih.gov/ pubmed/24495792 (дата обращения: 04.02.2021).
60. Karvinen S., Waller K., Silvennoinen M. et al. Physical activity in adulthood: genes and mortality. Sci Rep. 2015 Dec 15;5:18259. doi: 10.1038/srep18259. www. ncbi.nlm.nih.gov/pubmed/26666586 (дата обращения: 04.02.2021).
61. Kujala U.M., Kaprio J., Sarna S., Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. JAMA. 1998 Feb 11;279(6):440-4. doi: 10.1001/jama.279.6.440. www.ncbi.nlm.nih.gov/pubmed/9466636 (дата обращения: 04.02.2021).
62. Park J., Park H. Effects of 6 months of aerobic and resistance exercise training on carotid artery intima media thickness in overweight and obese older women. Geriatr Gerontol Int. 2017 Dec;17(12):2304–2310. doi: 10.1111/ggi.12972. www.ncbi.nlm.nih. gov/pubmed/28060442 (дата обращения: 04.02.2021).
63. Feairheller D.L., Diaz K.M., Kashem M.A. et al. Effects of moderate aerobic exercise training on vascular health and blood pressure in African Americans. J Clin Hypertens (Greenwich). 2014 Jul;16(7):504-10. doi: 10.1111/jch.12328. www.ncbi.nlm.nih.gov/ pubmed/24779748 (дата обращения: 04.02.2021).
64. Sternbach G. William Heberden and Myron Prinzmetal: angina pectoris. J Emerg Med. Jan-Apr 1991;9(1–2):81-3. doi: 10.1016/0736-4679(91)90543-o. www.ncbi.nlm. nih.gov/pubmed/2045655 (дата обращения: 04.02.2021).
65. Gielen S., Laughlin M.H., O’Conner C., Duncker D.J. Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations. Prog Cardiovasc Dis. Jan-Feb 2015;57(4):347-55. doi: 10.1016/j.pcad.2014.10.001. www. ncbi.nlm.nih.gov/pubmed/25459973 (дата обращения: 04.02.2021).
66. Boden W.E., O’Rourke R.A., Teo K.K. et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. www.ncbi.nlm.nih.gov/pubmed/17387127 (дата обращения: 04.02.2021).
67. Shaw L.J., Berman D.S., Maron D.J. et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/ CIRCULATIONAHA.107.743963. www.ncbi.nlm.nih.gov/pubmed/18268144 (дата обращения: 04.02.2021).
68. Hambrecht R., Niebauer J., Marburger C. et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol. 1993 Aug;22(2):468-77. doi: 10.1016/0735-1097(93)90051-2. www.ncbi.nlm.nih.gov/ pubmed/8335816 (дата обращения: 04.02.2021).
69. Skilton M.R., Yeo S.Q., Ne J.Y. et al. Weight loss and carotid intima-media thickness-a meta-analysis. Obesity (Silver Spring). 2017 Feb;25(2):357–362. doi: 10.1002/ oby.21732. www.ncbi.nlm.nih.gov/pubmed/28026904 (дата обращения: 04.02.2021).
70. Yamazaki Y., Emoto M., Morioka T. et al. Clinical impact of the leptin to soluble leptin receptor ratio on subclinical carotid atherosclerosis in patients with type 2 diabetes. J Atheroscler Thromb. 2013;20(2):186-94. doi: 10.5551/jat.14662. www.ncbi.nlm.nih. gov/pubmed/23124060 (дата обращения: 04.02.2021).
71. Ndabaneze E., Kadende P., Laroche R., Aubry P. [Epidemiologic aspects of gastroduodenal ulcer in Burundi. Apropos of 1,476 new cases seen in 3 years] Ann Gastroenterol Hepatol (Paris). 1989 Oct;25(5):205-9. [Article in French]. www.ncbi. nlm.nih.gov/pubmed/2817766 (дата обращения: 04.02.2021).
72. Ciccone M., Vettor R., Pannacciulli N. et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001 Jun;25(6):805-10. doi: 10.1038/sj.ijo.0801623. www.ncbi. nlm.nih.gov/pubmed/11439293 (дата обращения: 04.02.2021).
73. Martinez-Martinez E., Miana M., Jurado-Lopez R. et al. The potential role of leptin in the vascular remodeling associated with obesity. Int J Obes (Lond). 2014 Dec;38(12):1565-72. doi: 10.1038/ijo.2014.37. www.ncbi.nlm.nih.gov/pubmed/24583853 (дата обращения: 04.02.2021).
74. Li Y., Pan A., Wang D.D. et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018 Jul 24;138(4):345–355. doi: 10.1161/CIRCULATIONAHA.117.032047. www.ncbi.nlm.nih.gov/pubmed/29712712 (дата обращения: 04.02.2021).
75. Zhang X., Shu X.O., Xiang Y.B. et al. Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality. Am J Clin Nutr. 2011 Jul;94(1):240-6. doi: 10.3945/ajcn.110.009340. www.ncbi.nlm.nih.gov/ pubmed/21593509 (дата обращения: 04.02.2021).
76. Aune D., Giovannucci E., Boffetta P. et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol. 2017 Jun 1;46(3):1029–1056. doi: 10.1093/ije/dyw319. www.ncbi.nlm.nih.gov/pubmed/28338764 (дата обращения: 04.02.2021).
77. Mori N., Shimazu T., Charvat H. et al. Cruciferous vegetable intake and mortality in middle-aged adults: A prospective cohort study. Clin Nutr. 2019 Apr;38(2):631–643. doi: 10.1016/j.clnu.2018.04.012. www.ncbi.nlm.nih.gov/pubmed/29739681 (дата обращения: 04.02.2021).
78. Shawky N.M., Pichavaram P., Shehatou G.S. et al. Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. J Nutr Biochem. 2016 Jun;32:73–84. doi: 10.1016/j.jnutbio.2016.01.009. www. ncbi.nlm.nih.gov/pubmed/27142739 (дата обращения: 04.02.2021).